Abstract:Abstract Background The treatment of tuberous sclerosis complex (TSC) using mammalian target of rapamycin (mTOR) inhibitors is clinically promising. The aim of the present study was to evaluate the efficacy and safety of mTOR inhibitors for improving the clinical symptoms of TSC. Methods We performed a systematic search of major electronic databases (PubMed, EMBASE, Cochrane Library and WanFang, CNKI, and VIP databases) to identify randomized controlled trials (RCTs) and quasi-randomized studies from the date of database inception to November 2017; the Chinese Food and Drug Administration and clinicaltrials.gov were also searched for unpublished studies. The endpoints of the study were the tumor response rate and seizure frequency response rate (the proportion of patients achieving a ≥ 50% reduction relative to the baseline). Two researchers screened articles, assessed the risk of bias and extracted data independently. The included RCTs were analyzed using RevMan 5.3, which was provided by the Cochrane Collaboration. Results Compared with the placebo, mTOR inhibitors significantly reduced tumor volume in both angiomyolipoma (AML) (RR = 24.69, 95% CI = 3.51,173.41, P = 0.001) and subependymal giant cell astrocytoma (SEGA) (RR = 27.85, 95% CI = 1.74,444.82, P = 0.02). Compared with the placebo, mTOR inhibitors significantly reduced seizure frequency (RR = 2.12, 95% CI = 1.41,3.19, P = 0.0003). Regarding safety, compared with patients who did not receive mTOR inhibitors, those who did had a higher risk of suffering stomatitis (RR = 3.20, 95% CI = 1.49,6.86, P = 0.003). In contrast, patients who did and did not receive mTOR inhibitors experienced similar adverse events, such as upper respiratory tract infections (RR = 1.08, 95% CI = 0.81,1.45, P = 0.59) and nasopharyngitis (RR = 0.86, 95% CI = 0.60,1.21, P = 0.38). Conclusion In view of the efficacy and safety associated with tumor and seizure frequency in the TSC patients, mTOR inhibitors is a good therapeutic choice. Unlike the risks of upper respiratory tract infections and nasopharyngitis, mTOR inhibitors seem to increase the risk of stomatitis, mostly grade 1 and 2.

A Review of Research on mTOR Inhibitors

Overview of Research into mTOR Inhibitors

Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.

Furthering the Design and the Discovery of Small Molecule ATP-competitive Mtor Inhibitors As an Effective Cancer Treatment

Targeting mTOR globally in cancer: thinking beyond rapamycin.

Targeting Mtor for Fighting Diseases: A Revisited Review of Mtor Inhibitors

Biochemical and Pharmacological Inhibition of Mtor by Rapamycin and an ATP-Competitive Mtor Inhibitor

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Targeting the Mtor Kinase Domain: the Second Generation of Mtor Inhibitors

Advance in Research on the Relationship Between Mtor Signaling Pathway and Tumors

Biochemical, Cellular, and in Vivo Activity of Novel Atp-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Efficacy and Safety of Mtor Inhibitors (rapamycin and Its Analogues) for Tuberous Sclerosis Complex: a Meta-Analysis

Mammalian Target of Rapamycin Inhibitors and Tumor Therapy

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Mechanisms of mTOR inhibitor resistance in cancer therapy

Targeting Mtor for Cancer Therapy

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

Mechanisms of Rapamycin Inhibition on Mtor and Drug Design

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy

Targeting the mTOR pathway using deforolimus in cancer therapy

Research Progress of mTOR Inhibitors in the Treatment of Renal Cell Carcinoma